-Prosthetic Cranial Implant Receives Patent, Elevates Neurosurgical Precision and Patient Outcomes-
Link:
Neurotech Innovation Achieves Patent Approval and Featured Cover Story in Prominent Industry Journal
WARREN, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, filed a Registration Statement on Form S-1 (File No. 333-280414) on June 21, 2024, which was declared effective by the Securities and Exchange Commission on August 2, 2024, to register the issuance of earnout shares and shares underlying outstanding warrants to purchase the Company’s common stock as well as the resale of shares and warrants by existing securityholders. Today, Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities.
neffy Offers Adults and Children (?30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years
The rest is here:
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic...
Bagsværd, Denmark, 9 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Excerpt from:
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
More:
Sanofi: Information concerning the total number of voting rights and shares - July 2024
TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company’s U.S. Patent No. 11,033,495 (the ‘495 patent) is not valid.
See the original post here:
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
DURHAM, N.C., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced a delay in its previously announced public offering. The Company has requested, and the NYSE has approved, a financial viability exception to the NYSE American shareholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof, exclusive of the over-allotment option) at a price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). The underwriting agreement was terminated in connection with the previously announced offering and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing of a notification letter to the Company’s shareholders.
Originally posted here:
Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering
Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug Delivery Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug Delivery
Continue reading here:
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
– 2nd quarter conference call to be held Tuesday, August 13th, at 8:30 a.m. ET –
See the rest here:
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the...
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.
See original here:
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates